Vittorio Rosti

Pavia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 126 publications

Response to Comment on: "Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm."

Response to Comment on: "Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm."

Journal: Haematologica

Published: May 11, 2026

Are Myeloproliferative Neoplasms-Unclassifiable Really Unclassifiable?

Are Myeloproliferative Neoplasms-Unclassifiable Really Unclassifiable?

Journal: EJHaem

Published: March 07, 2026

Understanding the link between PMN-MDSCs and CXCL8-CXCR1/2 axis in primary myelofibrosis.

Understanding the link between PMN-MDSCs and CXCL8-CXCR1/2 axis in primary myelofibrosis.

Journal: Frontiers in cell and developmental biology

Published: February 11, 2026

Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.

Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.

Journal: Leukemia

Published: November 07, 2025

The influence of patient engagement and self-efficacy on self-care in myeloproliferative neoplasms: A mediation analysis.

The influence of patient engagement and self-efficacy on self-care in myeloproliferative neoplasms: A mediation analysis.

Journal: European journal of oncology nursing : the official journal of European Oncology Nursing Society

Published: October 29, 2025

Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.

Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.

Journal: Haematologica

Published: July 14, 2025

Primary myelofibrosis with increased haemoglobin concentration at presentation.

Primary myelofibrosis with increased haemoglobin concentration at presentation.

Journal: British journal of haematology

Published: April 03, 2025

Phase I Clinical Trial on Pleural Mesothelioma Using Neoadjuvant Local Administration of Paclitaxel-Loaded Mesenchymal Stromal Cells (PACLIMES Trial): Study Rationale and Design.

Phase I Clinical Trial on Pleural Mesothelioma Using Neoadjuvant Local Administration of Paclitaxel-Loaded Mesenchymal Stromal Cells (PACLIMES Trial): Study Rationale and Design.

Journal: Cancers

Published: August 14, 2024

Circulating Polymorphonuclear Myeloid-Derived Suppressor Cells (PMN-MDSCs) Have a Biological Role in Patients with Primary Myelofibrosis.

Circulating Polymorphonuclear Myeloid-Derived Suppressor Cells (PMN-MDSCs) Have a Biological Role in Patients with Primary Myelofibrosis.

Journal: Cancers

Published: May 17, 2024

Circulating Mesenchymal Stromal Cells in Patients with Infantile Hemangioma: Evaluation of Their Functional Capacity and Gene Expression Profile.

Circulating Mesenchymal Stromal Cells in Patients with Infantile Hemangioma: Evaluation of Their Functional Capacity and Gene Expression Profile.

Journal: Cells

Published: December 15, 2023

Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression?

Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression?

Journal: Blood cancer journal

Published: December 14, 2023

JAK2V617F and ischemic stroke: CHIP or CMD-NBV?

JAK2V617F and ischemic stroke: CHIP or CMD-NBV?

Journal: Blood advances

Published: November 06, 2023

Showing 1-12 of 126

Last Updated: 09/26/2026